Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-30

Study Completion Date

2019-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will establish a platform at Dartmouth-Hitchcock Medical Center to generate novel models of estrogen receptor alpha-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which will be used for research studies to develop novel treatment strategies and dissect signaling pathways underlying drug sensitivity and resistance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patient Derived Breast Cancer Xenografts

NCT01750164

Metastatic Breast Cancer

TERMINATED

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.

NCT02010021

Breast Cancer

COMPLETED NA

Biology Guided Therapy for Breast Cancer for ER Positive

NCT04965688

Breast Cancer Estrogen Receptor-positive Breast Cancer HER2-negative Breast Cancer

TERMINATED PHASE2

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

NCT07214532

Breast Neoplasms Carcinoma, Ductal, Breast Receptors, Estrogen (for ER-positive Requirement)

NOT_YET_RECRUITING NA

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337

Metastatic Breast Cancer

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women \> age 18 with histologically documented ER+/HER2- breast cancer or with a history of ER+/HER2- breast cancer, for whom a tumor biopsy or surgical resection is clinically indicated and will be performed as standard of care.

Tumor specimens may be from breast (progressive or recurrent) or metastatic sites. Patients with multicentric or bilateral disease are eligible.
2. Patients must have disease progression during neoadjuvant therapy, recurrence after neoadjuvant or adjuvant therapy, or progression after systemic therapy for metastatic disease.
3. ER positivity is defined as \>10% of malignant tumor cells staining positively for ER by immunohistochemistry (IHC).

HER2 negativity is defined as IHC 0-1+, or with a fluorescence in situ hybridization (FISH) ratio of \<1.8 if IHC is 2+ or if IHC has not been done.
4. Excess LIVE tumor tissue must be available from the surgically resected tumor specimen, or from 1-3 extra core needle or incisional biopsy. LIVE tumor tissue must be available within 2 hours of removal from patient (shorter time is preferable).
5. A recurrent or progressing breast cancer must be greater than 1 cm in greatest diameter.
6. Prior therapy is allowed as long as excess viable tumor tissue is available from the biopsy or surgical excision procedure.
7. Patients must be willing to provide 6 mL of blood, which can be obtained during a routine clinically indicated blood draw (ideally, done on the same day as the tumor biopsy/surgery).
8. Ability to give signed informed consent.